Use of Fixed-dose Combination Therapy with Remogliflozin and Vildagliptin as an Add-on Drug in Improving the Glycemic Control of Type 2 Diabetes Mellitus: An Observational Study

ABSTRACT

Objective: To evaluate whether a fixed dose combination (FDC) with remogliflozin and vildagliptin as an add-on therapy can improve the glycemic control in the management of type 2 diabetes mellitus and also the non-glycemic effects on physical profile, blood pressure, lipids, and insulin resistance. Materials and Methods: An observational study that included 50 poorly controlled diabetics from April 2021 to September 2021. Patients were divided into two groups – those who were prescribed this FDC by their treating physician as an add-on drug were formed as group 1 (n = 28). Comparison group was age-matched patients who received other standard antidiabetic medications, categorized as group 2 (n = 22). Fasting and postprandial sugars were done at baseline, the third and sixth month; glycated hemoglobin, body mass index, blood pressure, and lipids were done at baseline and the sixth month. Changes in blood sugar levels and glycated hemoglobin (HbA1C) at the third and sixth month from the baseline were compared using the Mann-Whitney U test. P-value less than 5% was considered statistically significant. Results: A statistically significant reduction in mean HbA1c was noted in group 1 [–1.80 (−3.20, −0.15)] when compared to group 2 [0.50 (0.05, 0.80)] at the end of the third month. At the end of the sixth month, a significant reduction in the HbA1c level was noted in group 1 [(7.83 ± 0.87 %) when compared to baseline (10.3 ± 1.75%)]. Change in PPBS value at the third month from baseline was also statistically significant between groups 1 and 2 (−62.0 mg%, 19.0, P = 0.003). With respect to the body mass index and blood pressure, we did not find any significant difference. Conclusion: The fixed drug combination improves glycemic control by significantly reducing mean HbA1c at the third and sixth month from baseline and there was no significant effect on body mass index, blood pressure, and lipids.

KEYWORDS

• Diabetes mellitus
• fixed-dose combination
• remogliflozin and vildagliptin
• glycemic control

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/0976500X231175219Copy

RELATED ARTICLES

Matched on volume, issue, section and article type within J Pharmacol. Pharmacother..

• Article · VOLUME 14, ISSUE 1Evaluation of Virtual Reality High-Fidelity Adult Mannequin-based Simulation of Real-Life Clinical Scenarios in Teaching Clinical Pharmacology to Medical StudentsAnupama M. Gudadappanavar, Prashant Hombal, Jyoti M. Benni, Sachin Patel, Basavaraj R. Tubaki · pp. 25–34Research ArticleSame type: ArticleSame issue
• Article · VOLUME 14, ISSUE 1Incidence, Patterns, and Severity of Potential Drug Interactions Among Cancer Patients on Chemotherapy in a Tertiary Care HospitalAnuradha H.V., Vinayak V. Maka, Prakash Patil, Anupama C. · pp. 35–40Research ArticleSame type: ArticleSame issue
• Article · VOLUME 14, ISSUE 1Critical Evaluation of Drug Promotional Literature Using WHO Ethical Criteria and Perception of Clinicians at a Tertiary Care HospitalAmanjot Kaur, Shweta Singla, Mandeep Kaur, Jasninder Singh · pp. 41–46Research ArticleSame type: ArticleSame issue
• Article · VOLUME 14, ISSUE 1An Observational Study on the Intraoperative Awareness Following General Anesthetic DrugsNikita Haldar, Krishna Prasad T., Mali Kalpana Ramanna, Maduram Annamalai, Soundarya Priyadharsini K. · pp. 47–53Research ArticleSame type: ArticleSame issue